Answers are grounded in this paper and cite their sources.
In vitro experimental study demonstrates broad antimicrobial and antiparasitic activity of novel triazole-sulfonamide conjugates, highlighting their potential as therapeutic lead structures.
Triazole-based compounds continue to attract considerable interest in medicinal chemistry, particularly for their diverse antimicrobial potential. In this study, a series of novel 1,2,3-triazole-sulfonamide conjugates (7a-h) were rationally designed and synthesised using the copper(I)-catalysed azide-alkyne cycloaddition (CuAAC) strategy. The synthesised molecules were thoroughly characterised and screened for different anti-microbial activities. Among the series, compound 7h , featuring a 2,5-dichlorophenyl moiety, emerged as the most biologically active candidate, displaying activity against Escherichia coli with an MIC value of 50 µg/mL, Candida albicans with an MIC value of 250 µg/mL, Plasmodium falciparum with an IC₅₀ value of 0.62 µg/mL, and Mycobacterium tuberculosis with an MIC value of 50 µg/mL. SAR analysis revealed that chloro-substitution on the sulfonamide ring plays a critical role in enhancing the biological profiles of the compounds. These results underscore the potential of triazole-sulfonamide hybrids as versatile lead structures for the development of next-generation antimicrobial and antiparasitic therapeutics.
No takes yet. Share an insight, caveat, or question.
Pagar et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: